Genpact price target lowered to $54 from $56 at Baird

Baird analyst David Koning lowered the firm’s price target on Genpact to $54 from $56 and keeps an Outperform rating on the shares. The analyst said Q3 results were good and 2022 guidance was raised on constant-fx basis, but implied Q4 guidance calls for slowdown, but he continues to like the theme of general stability in a tough macro.